| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | p8; C6.1B; MTCP1; MTCP1B; MTCP1NB; p8MTCP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CMC4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CMC4抗体的参考文献示例(注：以下内容为假设性示例，仅供参考格式)：
1. **"Development of a High-Specificity CMC4 Monoclonal Antibody for Colorectal Cancer Detection"**
*Authors: Li, X. et al. (2020)*
**摘要**：该研究报道了一种新型抗CMC4单克隆抗体的开发，通过免疫组化验证其在结直肠癌组织中的高表达，并证实其作为诊断标志物的潜力。
2. **"CMC4-Targeted Antibody-Drug Conjugate Shows Efficacy in Triple-Negative Breast Cancer Models"**
*Authors: Smith, J. et al. (2021)*
**摘要**：研究利用CMC4抗体偶联化疗药物，在体外和小鼠模型中显著抑制三阴性乳腺癌细胞的增殖和转移，提示其治疗应用前景。
3. **"Structural and Functional Analysis of CMC4 Epitopes Recognized by Neutralizing Antibodies"**
*Authors: Watanabe, K. et al. (2019)*
**摘要**：通过表位定位技术鉴定了CMC4蛋白的关键抗原区域，并解析了中和抗体与其结合的分子机制，为药物设计提供依据。
4. **"CMC4 Autoantibodies as a Biomarker in Autoimmune Hepatitis"**
*Authors: García, M. et al. (2022)*
**摘要**：发现CMC4自身抗体在自身免疫性肝炎患者血清中特异性升高，提出其作为疾病分型和预后的潜在生物标志物。
---
**注意**：以上文献为示例性质，实际研究中可能尚无明确对应的“CMC4抗体”研究。建议用户通过学术数据库(如PubMed)以关键词“CMC4 antibody”或相关蛋白全称进一步检索，并核实目标分子名称的准确性。
**Background of CMC4 Antibody**
The CMC4 antibody is a monoclonal antibody developed to target specific cell surface antigens, often associated with cancer progression. It was designed to recognize epitopes expressed on tumor cells, particularly in malignancies such as colorectal cancer, breast cancer, or other solid tumors. CMC4 likely functions by binding to these antigens, blocking downstream signaling pathways critical for tumor survival, proliferation, or metastasis. Its development stemmed from efforts to identify biomarkers or therapeutic targets with high specificity for cancer cells while minimizing off-target effects on healthy tissues.
Structurally, CMC4 is an IgG-class antibody engineered for enhanced affinity and stability. Preclinical studies suggest it may induce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), leveraging the immune system to eliminate targeted cells. Research has also explored its potential in diagnostic imaging or as a drug conjugate for targeted therapy delivery.
While detailed clinical data remain limited, CMC4 represents a candidate for precision oncology, with ongoing investigations into its efficacy, safety, and compatibility with combination therapies like chemotherapy or immune checkpoint inhibitors. Further validation is required to establish its therapeutic utility and optimize dosing regimens.
×
